$GOVX
GeoVax Labs, Inc.

2015 Q4 Form 10-Q Financial Statement

#000143774915020553 Filed on November 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $160.1K $93.13K $322.1K
YoY Change -28.26% -71.09% -67.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $330.0K $340.0K $410.0K
YoY Change -51.47% -17.07% 28.13%
% of Gross Profit
Research & Development $530.0K $378.5K $425.5K
YoY Change 12.77% -11.04% -51.6%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $20.00K
YoY Change -50.0% -50.0% 100.0%
% of Gross Profit
Operating Expenses $850.0K $714.5K $837.3K
YoY Change -26.09% -14.67% -29.96%
Operating Profit -$621.3K -$515.2K
YoY Change 20.59% 169.27%
Interest Expense $0.00 $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.424K $711.00
YoY Change 100.28% -40.6%
Pretax Income -$690.0K -$620.0K -$510.0K
YoY Change -25.0% 21.57% 168.42%
Income Tax
% Of Pretax Income
Net Earnings -$692.7K -$619.9K -$514.5K
YoY Change -25.0% 20.48% 170.59%
Net Earnings / Revenue -432.81% -665.63% -159.74%
Basic Earnings Per Share -$0.02 -$0.02 -$0.02
Diluted Earnings Per Share -$433.6B -$388.0B -$406.3B
COMMON SHARES
Basic Shares Outstanding 31.95M
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.060M $1.820M $860.0K
YoY Change -3.64% 111.63% -50.0%
Cash & Equivalents $1.060M $1.821M $862.2K
Short-Term Investments
Other Short-Term Assets $60.00K $80.00K $60.00K
YoY Change 50.0% 33.33% 20.0%
Inventory
Prepaid Expenses
Receivables $120.0K $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.237M $1.896M $926.4K
YoY Change 0.94% 104.7% -48.25%
LONG-TERM ASSETS
Property, Plant & Equipment $83.61K $90.84K $113.2K
YoY Change -13.53% -19.77% -19.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.01K $10.00K $13.51K
YoY Change 0.0% -25.98% 35.1%
Total Long-Term Assets $94.62K $101.9K $126.7K
YoY Change -12.15% -19.64% -25.45%
TOTAL ASSETS
Total Short-Term Assets $1.237M $1.896M $926.4K
Total Long-Term Assets $94.62K $101.9K $126.7K
Total Assets $1.332M $1.998M $1.053M
YoY Change -0.12% 89.74% -46.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $100.9K $42.49K $82.20K
YoY Change 81.49% -48.3% -8.67%
Accrued Expenses $26.06K $5.000K $8.279K
YoY Change -50.36% -39.61% -93.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $127.0K $118.2K $170.2K
YoY Change -32.1% -30.55% -25.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $127.0K $118.2K $170.2K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $130.0K $120.0K $170.0K
YoY Change -31.58% -29.41% -26.09%
SHAREHOLDERS EQUITY
Retained Earnings -$32.47M -$31.78M
YoY Change 9.03%
Common Stock $32.62M $32.60M $28.89M
YoY Change 5.72% 12.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.205M $1.880M $882.9K
YoY Change
Total Liabilities & Shareholders Equity $1.332M $1.998M $1.053M
YoY Change -0.12% 89.74% -46.27%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$692.7K -$619.9K -$514.5K
YoY Change -25.0% 20.48% 170.59%
Depreciation, Depletion And Amortization $10.00K $10.00K $20.00K
YoY Change -50.0% -50.0% 100.0%
Cash From Operating Activities -$770.0K -$650.0K -$490.0K
YoY Change 22.22% 32.65% 600.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$30.00K
YoY Change -100.0% -66.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$30.00K
YoY Change -100.0% -66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -770.0K -650.0K -490.0K
Cash From Investing Activities 0.000 0.000 -30.00K
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -770.0K -650.0K -520.0K
YoY Change -420.83% 25.0% 225.0%
FREE CASH FLOW
Cash From Operating Activities -$770.0K -$650.0K -$490.0K
Capital Expenditures $0.00 $0.00 -$30.00K
Free Cash Flow -$770.0K -$650.0K -$460.0K
YoY Change 22.22% 41.3% -2400.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31950813
dei Entity Voluntary Filers
EntityVoluntaryFilers
No
dei Trading Symbol
TradingSymbol
govx
dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015Q3 govx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
39775491
CY2015Q3 govx Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable
0.21
CY2015Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
56442157
CY2015Q3 govx Unused Grant Funds
UnusedGrantFunds
260522
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
42492
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
55616
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
52490
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
579404
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
557703
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
32570153
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
30823769
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
51983
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
193803
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16926
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24573
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50516
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
165638
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
79000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12500000
CY2015Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
8400
CY2015Q3 us-gaap Assets
Assets
1998165
CY2014Q4 us-gaap Assets
Assets
1333198
CY2015Q3 us-gaap Assets Current
AssetsCurrent
1896313
CY2014Q4 us-gaap Assets Current
AssetsCurrent
1225495
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basis of Presentation</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying condensed consolidated financial statements at September 30, 2015 and for the three-month and nine-month periods ended September 30, 2015 and 2014 are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of the dates and periods presented. Interim results are not necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2014. We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods. </div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of the financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine candidates. We have funded our activities to date from government grants and clinical trial assistance, and from sales of our equity securities. We will continue to require substantial funds to continue our research and development activities. We believe that our existing cash resources and grant commitments will be sufficient to fund our planned operations through the first quarter of 2016, but due to our history of operating losses and our continuing need for capital to conduct our research and development activities, there is substantial doubt concerning our ability to operate as a going concern beyond that date. We are currently exploring sources of capital through government grants and clinical trial support and through philanthropic foundation support. We may also secure additional funds through sales of our equity securities or the exercise of currently outstanding stock purchase warrants. Management believes that the Company&#x2019;s demonstrated history of successful funding through both government sources and equity securities alleviate the substantial doubt about the Company&#x2019;s ability to operate as a going concern. However, additional funding may not be available on favorable terms or at all. If we fail to obtain additional capital when needed, we may be required to delay, scale back, or eliminate some or all of our research and development programs as well as reduce our general and administrative expenses.</div></div></div>
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1101651
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2513861
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1821037
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
862191
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
719386
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1651670
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.66
CY2015Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.20
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
49999998
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5108826
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
79052160
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31950813
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31950813
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31950813
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31950813
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
31951
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
31951
CY2015Q3 us-gaap Deposits Assets
DepositsAssets
11010
CY2014Q4 us-gaap Deposits Assets
DepositsAssets
11010
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21701
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
50003
CY2015Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
70729
CY2014Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
78917
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
64330
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y182D
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
335932
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
411814
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1102262
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1128478
CY2015Q3 us-gaap Grants Receivable
GrantsReceivable
CY2014Q4 us-gaap Grants Receivable
GrantsReceivable
79341
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-68802
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-142116
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
30773
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
20631
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-79341
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-140909
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1424
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
711
us-gaap Investment Income Interest
InvestmentIncomeInterest
4481
us-gaap Investment Income Interest
InvestmentIncomeInterest
3201
us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P1Y
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1998165
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1333198
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
118221
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
187023
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Description of Company </div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">GeoVax Labs, Inc. (&#x201c;GeoVax&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company developing human vaccines using our novel platform technology. Our current development programs are focused on vaccines against Ebola and Marburg viruses, and Human Immunodeficiency Virus (HIV). Our vaccine delivery technology generates virus-like particles (VLPs) that are effective at eliciting safe and effective immune responses. Our proprietary Ebola vaccine technology has been developed internally using technology licensed from the National Institutes of Health (NIH), while our HIV vaccine technology was developed in collaboration with Emory University, the NIH, and the</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> Centers for Disease Control and Prevention (CDC) and is exclusively licensed to us.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia. </div></div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2679809
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15850
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35503
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1944573
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1616167
us-gaap Net Income Loss
NetIncomeLoss
-1996556
us-gaap Net Income Loss
NetIncomeLoss
-1809970
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-619899
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-514515
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1424
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
711
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4481
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3201
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
714453
us-gaap Operating Expenses
OperatingExpenses
2269065
us-gaap Operating Expenses
OperatingExpenses
2473038
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-621323
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-515226
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
837312
us-gaap Operating Income Loss
OperatingIncomeLoss
-2001037
us-gaap Operating Income Loss
OperatingIncomeLoss
-1813171
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
149042
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
36523
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15850
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35503
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
75276
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
44503
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
2679809
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
CY2015Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
670246
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
654396
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
90842
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
96693
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
378521
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
425498
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1166803
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1344560
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31782196
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29785640
CY2015Q3 us-gaap Revenue From Grants
RevenueFromGrants
93130
CY2014Q3 us-gaap Revenue From Grants
RevenueFromGrants
322086
us-gaap Revenue From Grants
RevenueFromGrants
268028
us-gaap Revenue From Grants
RevenueFromGrants
659867
us-gaap Share Based Compensation
ShareBasedCompensation
50516
us-gaap Share Based Compensation
ShareBasedCompensation
165638
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
720094
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
68000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
41400
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1183100
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1156500
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.50
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.50
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.15
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
1879944
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
1146175
CY2015Q3 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
36200
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31950813
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25325141
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31950813
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25109811

Files In Submission

Name View Source Status
0001437749-15-020553-index-headers.html Edgar Link pending
0001437749-15-020553-index.html Edgar Link pending
0001437749-15-020553.txt Edgar Link pending
0001437749-15-020553-xbrl.zip Edgar Link pending
ex10-7.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
govx-20150930.xml Edgar Link completed
govx-20150930.xsd Edgar Link pending
govx-20150930_cal.xml Edgar Link unprocessable
govx-20150930_def.xml Edgar Link unprocessable
govx-20150930_lab.xml Edgar Link unprocessable
govx-20150930_pre.xml Edgar Link unprocessable
govx20150930_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending